Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Covidien Lines Up More Technetium
by Michael McCoy
March 15, 2010
| A version of this story appeared in
Volume 88, Issue 11
Covidien will obtain molybdenum-99 from Poland’s Maria Research Reactor for the manufacture of technetium-99m, an isotope used in more than 80% of all nuclear medicine procedures. FDA and Health Canada have approved the Maria reactor, according to Covidien, a major medical imaging company. Technetium-99m has been in short supply for the past year because of an outage at Canada’s Chalk River reactor, which supplies about half the world’s molybdenum-99. Atomic Energy of Canada said last week that the restart has been delayed by about a month until May.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter